drugset
Drugs / ISIS-APO(a)Rx
last change Nov 2015 re-read 3 minutes ago

ISIS-APO(a)Rx

Developed for
hyperlipoproteinemia
Investigated by
Ionis Pharmaceuticals, Inc.

Trials 1

today NCT02160899 · Ph 2
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02160899 Jun 2014 → Nov 2015 hyperlipoproteinemia Ionis Pharmaceuticals, Inc. Completed Met primary

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2015-11-08 Ionis Pharmaceuticals Results Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs ionis.com ↗
2015-07-22 Ionis Pharmaceuticals Results Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet ionis.com ↗
2014-09-02 Ionis Pharmaceuticals Results Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014 ionis.com ↗
Data from the Phase 1 study of ISIS-APO(a)Rx in which treatment with ISIS-APO(a)Rx produced dose-dependent and significant reductions in Lp(a) levels in healthy volunteers.
2013-11-16 Ionis Pharmaceuticals Results Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive results from a Phase 1 study with ISIS-APO(a)Rx.

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ISIS-APO(a)Rx ClinicalTrials.gov intervention name — accepted as the source's own label NCT02160899 ↗
Route Subcutaneous “ISIS-APO(a)Rx subcutaneously” NCT02160899 ↗